886366-09-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-fluorophenyl)pyridin-4-amine is used as a building block for the synthesis of pharmaceuticals. Its unique structure and reactivity contribute to the development of new drugs, potentially offering novel therapeutic options for a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(4-fluorophenyl)pyridin-4-amine serves as a key intermediate in the production of agrochemicals. Its incorporation into these compounds can lead to the creation of effective pesticides or other agricultural products designed to protect crops and enhance yield.
Used in Organic Synthesis:
2-(4-fluorophenyl)pyridin-4-amine is utilized as a valuable intermediate in organic synthesis. Its presence in the synthesis process allows for the creation of a variety of organic compounds, expanding the range of available chemical products and materials.

InChI:InChI=1/C11H9FN2/c12-9-3-1-8(2-4-9)11-7-10(13)5-6-14-11/h1-7H,(H2,13,14)

Upstream product

• 14432-12-3 4-Amino-2-chloropyridine 
• 1765-93-1 4-fluoroboronic acid 

Relevant academic research and scientific papers

Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology

The tumor microenvironment contains high concentrations of TGFβ, a crucial immunosuppressive cytokine. TGFβ stimulates immune escape by promoting peripheral immune tolerance to avoid tumoricidal attack. Small-molecule inhibitors of TGFβR1 are a prospective method for next-generation immunotherapies. In the present study, we identified selective 4-aminoquinoline-based inhibitors of TGFβR1 through structural and rational-based design strategies. This led to the identification of compound 4i, which was found to be selective for TGFβR1 with the exception of MAP4K4 in the kinase profiling assay. The compound was then further optimized to remove MAP4K4 activity, since MAP4K4 is vital for proper T-cell function and its inhibition could exacerbate tumor immunosuppression. Optimization efforts led to compound 4s that inhibited TGFβR1 at an IC50 of 0.79 ± 0.19 nM with 2000-fold selectivity against MAP4K4. Compound 4s represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology.

NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS

The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.

New catalysts for Suzuki-Miyaura coupling reactions of heteroatom- substituted heteroaryl chlorides

(Chemical Equation Presented) The new air-stable PdCl2{PR 2(Ph-R′)}2 complexes, readily prepared from commercial reagents, exhibit unique efficiency as catalysts for the Suzuki-Miyaura coupling reactions of a variety of he